Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;41(3):663-5.
doi: 10.1038/npp.2015.260. Epub 2015 Aug 25.

Abuse of New Psychoactive Substances: Threats and Solutions

Michael H Baumann  1 , Nora D Volkow  2
Affiliations

Abuse of New Psychoactive Substances: Threats and Solutions

Michael H Baumann et al. Neuropsychopharmacology. 2016 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Law enforcement encounters of methylone, MDPV and selected replacement analogs from 2010 to 2014. Data are gleaned from the National Forensic Laboratory Information System Special Report- http://www.deadiversion.usdoj.gov/nflis/spec_rpt_CathCan_2013.pdf and from personal communications with the DEA. Upper panel shows data for methylone and its analogs, whereas bottom panel shows data for MDPV and its analogs. The dashed arrow represents emergency scheduling of methylone and MDPV in 2011.
See this image and copyright information in PMC

References

    1. Baumann MH, Solis E, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL (2014). Bath salts, spice and related designer drugs: the science behind the headlines. J Neurosci 34: 15150–15158. - PMC - PubMed
    1. Brandt SD, King LA, Evans-Brown M (2014). The new drug phenomenon. Drug Test Anal 6: 587–597. - PubMed
    1. Drug Enforcement Administration (2014). Special report: synthetic cannabinoids and cathinones reported in NFLIS, 2010-2013 http://www.deadiversion.usdoj.gov/nflis/spec_rpt_CathCan_2013.pdf.
    1. Nutt DJ, King LA, Nichols DE (2013). Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci 14: 577–585. - PubMed
    1. Trecki J, Gerona RR, Schwartz MD (2015). Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373: 103–107. - PubMed

Publication types

Substances